Genetic Alteration of p18^INK4C and its Expression in Peripheral Blood Mononuclear Cells Were Not Associated With Progression-free Survival of Multiple Myeloma Patients After Autologous Stem Cell Transplant.

IF 1.6 4区医学 Q4 ONCOLOGY Anticancer research Pub Date : 2024-09-01 DOI:10.21873/anticanres.17201

Junan Li, Ming J Poi

{"title":"Genetic Alteration of p18INK4C and its Expression in Peripheral Blood Mononuclear Cells Were Not Associated With Progression-free Survival of Multiple Myeloma Patients After Autologous Stem Cell Transplant.","authors":"Junan Li, Ming J Poi","doi":"10.21873/anticanres.17201","DOIUrl":null,"url":null,"abstract":"Background/aim: The tumor suppressor CDKN2C (also designed as p18INK4C or p18) is deleted in approximately 7% to 40% of multiple myeloma (MM) patients, indicative of its potential association with myeloma pathogenesis.Materials and methods: A quantitative real-time PCR-based assay was developed to determine p18 deletion in DNA from peripheral blood mononuclear cells (PBMCs) in a cohort of 108 multiple myeloma patients after autologous stem cell transplant (ASCT). Additionally, the p18 mRNA expression level in PBMCs was quantitatively assessed using Taqman® gene expression assays.Results: p18 was homozygously and hemizygously deleted in PBMCs from 3 (2.8%) and 5 (4.6%) patients, respectively. Neither the p18 deletion nor the p18 mRNA levels in PBMCs were associated with progression-free survival (PFS), 90-day response, and the occurrence of severe mucositis in these patients (all p-values >0.20).Conclusion: Neither p18 deletion nor p18 mRNA expression in PBMCs can be used as a prognostic biomarker in MM patients.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":null,"pages":null},"PeriodicalIF":1.6000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17201","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: The tumor suppressor CDKN2C (also designed as p18^INK4C or p18) is deleted in approximately 7% to 40% of multiple myeloma (MM) patients, indicative of its potential association with myeloma pathogenesis.

Materials and methods: A quantitative real-time PCR-based assay was developed to determine p18 deletion in DNA from peripheral blood mononuclear cells (PBMCs) in a cohort of 108 multiple myeloma patients after autologous stem cell transplant (ASCT). Additionally, the p18 mRNA expression level in PBMCs was quantitatively assessed using Taqman^® gene expression assays.

Results: p18 was homozygously and hemizygously deleted in PBMCs from 3 (2.8%) and 5 (4.6%) patients, respectively. Neither the p18 deletion nor the p18 mRNA levels in PBMCs were associated with progression-free survival (PFS), 90-day response, and the occurrence of severe mucositis in these patients (all p-values >0.20).

Conclusion: Neither p18 deletion nor p18 mRNA expression in PBMCs can be used as a prognostic biomarker in MM patients.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

p18INK4C的基因改变及其在外周血单核细胞中的表达与多发性骨髓瘤患者自体干细胞移植后的无进展生存期无关

背景/目的：约7%至40%的多发性骨髓瘤（MM）患者体内存在肿瘤抑制因子CDKN2C（也被设计为p18INK4C或p18）的缺失，这表明它可能与骨髓瘤的发病机制有关：研究人员开发了一种基于实时定量 PCR 的检测方法，以确定 108 例自体干细胞移植（ASCT）后多发性骨髓瘤患者外周血单核细胞（PBMC）DNA 中的 p18 缺失。结果显示：在3名（2.8%）和5名（4.6%）患者的外周血单个核细胞中，p18分别出现同源和半同源缺失。PBMCs中的p18缺失和p18 mRNA水平均与这些患者的无进展生存期（PFS）、90天反应和严重粘膜炎的发生无关（所有P值均大于0.20）：结论：PBMC 中的 p18 缺失和 p18 mRNA 表达均不能作为 MM 患者的预后生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.